Market Currents
The rise in BioSante Pharmaceuticals (BPAX -13.2%) is attributable to frenzied day trading of a...
-
Thursday, February 16, 2012, 12:29 PM ETThe rise in BioSante Pharmaceuticals (BPAX -13.2%) is attributable to frenzied day trading of a new momo favorite, according to biotech analyst Adam Feuerstein. He also remains underwhelmed with the FDA approval the company landed for its testosterone-boosting gel given that 5 competing products are already in the market. Despite today's selloff, BPAX is on a +67.6% YTD bender.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
